Achilles Therapeutics plc Quarterly Comprehensive Income (Loss), Net of Tax, Attributable to Parent in USD from Q2 2022 to Q2 2024
-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.
-
Summary
-
Achilles Therapeutics plc quarterly/annual Comprehensive Income (Loss), Net of Tax, Attributable to Parent history and growth rate from Q2 2022 to Q2 2024.
- Achilles Therapeutics plc Comprehensive Income (Loss), Net of Tax, Attributable to Parent for the quarter ending June 30, 2024 was -$16.2M, a 24.2% decline year-over-year.
- Achilles Therapeutics plc annual Comprehensive Income (Loss), Net of Tax, Attributable to Parent for 2023 was -$61M, a 38.7% increase from 2022.
- Achilles Therapeutics plc annual Comprehensive Income (Loss), Net of Tax, Attributable to Parent for 2022 was -$99.5M, a 49% decline from 2021.
- Achilles Therapeutics plc annual Comprehensive Income (Loss), Net of Tax, Attributable to Parent for 2021 was -$66.8M, a 130% decline from 2020.
Comprehensive Income (Loss), Net of Tax, Attributable to Parent, Quarterly (USD)
Comprehensive Income (Loss), Net of Tax, Attributable to Parent, YoY Quarterly Growth (%)